Core One Labs Enters Into LOI For First Sale Of Its Psychedelic Compounds
Core One Labs Enters Into LOI For First Sale Of Its Psychedelic Compounds
GMP Drug Inc., a wholly-owned subsidiary of Core One Labs Inc. (OTCQB:CLABF) (CSE:COOL)(Frankfurt:LD6) (WKN: A3CSSU) has entered into a non-binding letter of intent with Zollaris Laboratories Corporation, an arms-length party, in pursuit of a potential transaction involving the sale by GMP Drug of psychedelic compounds including but not limited to biosynthetic psilocybin, psilocin, DMT formulated by Vocan Biotechnologies Inc. and Awakened Biosciences Inc., each also wholly-owned subsidiaries of Core One.
GMP Drug Inc.，的全資子公司 Core One Labs Inc (OTCQB: CLABF) (CSE: COOL) (法蘭克福:LD6) (WKN: A3CSSU) 有 與 Zollaris 實驗室公司簽訂了一份不具約束力的意向書，一個獨立的當事方，正在進行一項涉及 銷售 作者：GMP 藥物 的迷幻化合物，包括但不限於生物合成的 psilocybin、psilocin、DMT 制定者 沃肯生物技術公司 和 Awakened Biosciences，兩家公司也是Core One的全資子公司。
Zollaris is a licensed pharmaceutical company that currently holds a license to possess, and conduct laboratory analysis on, psilocybin. The LOI proposes that GMP Drug will enter an arrangement in which Awakened and Vocan will formulate and GMP Drug will supply proprietary psychedelics produced using the patent-pending production methods of Awakened and Vocan, to Zollaris, pursuant to a definitive agreement, the terms of which are currently under negotiation. It is anticipated that the proprietary psychedelic compounds will be supplied to Zollaris at an agreed upon cost per gram, and in amounts requested by Zollaris.
Zollaris是一家持牌製藥公司，目前持有持有psilocybin並對其進行實驗室分析的許可證。意向書提議，GMP Drug將達成一項安排，根據最終協議，Awakened和Vocan將配製，GMP Drug將向Zollaris提供使用Awakened和Vocan正在申請專利的生產方法生產的專有迷幻藥，協議條款目前正在談判中。預計專有的迷幻化合物將按商定的每克成本和Zollaris要求的數量提供給Zollaris。
The definitive agreement is anticipated to incorporate the principal terms set forth in the LOI and, in addition, such other terms and provisions of a more detailed nature as the parties may agree upon and as are customary for transactions of this nature. The consummation of the final supply arrangement is subject to a number of conditions, including the satisfaction of each party's respective due diligence, the negotiation and execution of the definitive agreement and Zollaris holding a valid controlled substances license from Health Canada permitting the acquisition and possession of psilocybin.
預計最終協議將納入意向書中規定的主要條款，此外還包括雙方可能商定的以及此類性質交易的慣常性質更詳細的其他條款和條款。最終供應安排的完成受許多條件的約束，包括雙方各自的盡職調查得到滿足、最終協議的談判和執行，以及Zollaris持有加拿大衛生部頒發的允許購買和擁有psilocybin的有效受控物質許可證。
Photo: Benzinga edit with photos by geralt and sergeitokmakov on Pixabay
照片：Benzinga 在 Pixabay 上用 geralt 和 sergeitokmakov 的照片進行編輯
Benzinga Cannabis Capital Conference
本辛加大麻資本會議
The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.
Benzinga Cannabis Capital Conference是達成交易的地方，將於9月27日至28日重返芝加哥參加第17屆會議。在價格上漲之前立即獲取門票，並在大麻投資和品牌的中心佔有一席之地。
Related News
相關新聞
Core One In Talks With Multiple Companies To Supply Psilocybin
Core One 正在與多家公司就供應 psilocybin 進行談判